Older Adults with COPD Were Prescribed Synthetic Cannabinoids More Often, and at Higher Doses, Than Those Without the Disease

A large Ontario population study spanning a decade finds that off-label synthetic oral cannabinoid prescribing was twice as common among older adults with COPD compared to those without the disease, with longer durations and higher doses observed, raising respiratory safety questions that remain entirely unanswered by this descriptive design.

Why This Matters

Chronic obstructive pulmonary disease affects millions of older adults worldwide, and its symptom burden, particularly pain, nausea, and appetite loss from comorbid conditions, drives interest in off-label therapeutic options including synthetic cannabinoids like nabilone and dronabinol. These agents carry plausible but unconfirmed respiratory risks including respiratory depression, airway muscle relaxation, and immune modulation, all of which could be especially consequential in a population with already compromised lung function. Understanding how frequently these drugs are actually being prescribed to vulnerable respiratory patients, and in what patterns, is a necessary first step before safety studies can be designed and prescribing guidance developed.

Clinical Summary

COPD is the third leading cause of death globally, and older adults living with the disease frequently contend with multiple comorbidities that may prompt off-label prescribing of synthetic oral cannabinoids. This retrospective population-based cohort study, conducted by Vozoris and colleagues using 12 linked Ontario health administrative databases covering the period from 2005 to 2015, examined incident dispensing of nabilone and dronabinol among adults aged 66 and older. The mechanistic rationale for concern centers on known cannabinoid receptor activity in the respiratory system: CB1 receptor agonism can reduce respiratory drive and relax airway smooth muscle, while immunomodulatory effects mediated through CB2 receptors could theoretically increase infection susceptibility in lungs already compromised by COPD.

The study identified 172,282 older adults with COPD and 1,068,256 without, finding that incident synthetic cannabinoid use occurred in 0.6% of the COPD cohort versus 0.3% of those without COPD, a statistically significant difference (p<0.001). Among those who did receive these agents, COPD patients used them for longer durations and more frequently at higher doses than non-COPD users. Multiple logistic regression identified patient characteristics associated with incident use, though the study cannot explain prescriber reasoning. Critical limitations include the restriction to publicly insured adults aged 66 and older, the inability to determine clinical indication for prescribing, the pre-legalization study period, and the fundamental constraint that no clinical outcomes were assessed. The authors emphasize that dedicated prospective safety studies are needed before any conclusions about harm can be drawn.

Dr. Caplan’s Take

This study does something genuinely useful: it quantifies a prescribing pattern that many of us have suspected but never had population-level data to characterize. The finding that COPD patients receive synthetic cannabinoids at twice the rate of non-COPD patients, and at higher doses for longer periods, is worth knowing. But the gap between observing this pattern and concluding it represents a safety problem is enormous. When patients with COPD ask me whether nabilone or dronabinol might help their pain or appetite, they deserve an honest answer: we do not have outcome data showing these drugs are either harmful or safe in their specific respiratory context.

In practice, I approach synthetic cannabinoid prescribing in COPD patients with caution but not reflexive avoidance. If a patient has a legitimate indication such as refractory nausea or pain inadequately managed by first-line therapies, I start at the lowest effective dose, monitor respiratory symptoms closely, and reassess frequently. What I do not do is extrapolate from mechanistic speculation to deny a potentially beneficial therapy. We need the outcomes data this study was never designed to provide.

Clinical Perspective

This study sits at the very beginning of the research arc for cannabinoid safety in COPD. It establishes that a utilization signal exists but says nothing about whether the signal corresponds to clinical harm. For clinicians, the evidence currently supports awareness, not restriction. There is no basis in this study for recommending against synthetic cannabinoids in COPD patients who have appropriate indications; equally, there is no basis for assuming safety. The prescribing patterns observed, particularly the higher doses and longer durations in COPD patients, could reflect greater symptom burden in this population rather than reckless prescribing, a distinction this study cannot make.

From a pharmacological standpoint, both nabilone and dronabinol are CB1 receptor agonists with known central nervous system depressant effects that could theoretically compound respiratory depression, particularly in patients using concurrent opioids or benzodiazepines, both of which are common in older COPD populations. Clinicians should review full medication lists for additive sedation risk before prescribing. The single most actionable recommendation from this study is this: if you are prescribing synthetic oral cannabinoids to older adults with COPD, document the indication explicitly, use the lowest effective dose, and schedule follow-up that includes respiratory symptom monitoring, because the outcomes data that would guide you more precisely do not yet exist.

Study at a Glance

Study Type

Retrospective population-based cohort study (drug utilization analysis)

Population

Ontario adults aged 66 and older with public drug coverage (172,282 with COPD; 1,068,256 without COPD)

Intervention

Incident dispensing of off-label nabilone or dronabinol

Comparator

Older adults without COPD in the same database

Primary Outcomes

Incidence, duration, and dose of synthetic oral cannabinoid prescribing

Sample Size

1,240,538 total

Journal

Not specified in available data

Year

Study period 2005 to 2015

DOI or PMID

Not available in provided data

Funding Source

Not specified in available data

What Kind of Evidence Is This

This is a retrospective population-based cohort study analyzing drug utilization patterns through linked administrative databases. It sits in the lower-to-middle tier of the evidence hierarchy: above case reports and expert opinion, but well below randomized controlled trials or prospective cohort studies with clinical outcome measurement. The single most important inference constraint is that this design can describe prescribing patterns but cannot determine whether those prescriptions caused benefit, harm, or neither in the patients who received them.

How This Fits With the Broader Literature

This study addresses a notable gap. While prior research has examined cannabinoid pharmacology in respiratory disease at the bench level and small clinical case series have raised theoretical safety concerns, population-level prescribing data specific to COPD patients have been largely absent. The utilization findings are broadly consistent with the general trend of off-label cannabinoid prescribing growth documented in Canadian pharmacy databases during this period. However, the COPD-specific signal, particularly the higher doses and longer durations, is a novel observation that has not been previously quantified at this scale. The study extends the literature by providing a descriptive foundation that future pharmacovigilance and outcomes research can build upon, though it does not confirm or refute the mechanistic safety concerns raised by preclinical cannabinoid receptor studies in airway and immune tissue.

Common Misreadings

The most likely overinterpretation is concluding that synthetic cannabinoids are harmful to older adults with COPD. This study measured prescribing frequency, dose, and duration. It did not measure exacerbation rates, hospitalizations, respiratory function decline, or mortality. The mechanistic concerns about respiratory depression, aspiration risk, and immune suppression cited by the authors are biologically plausible hypotheses drawn from pharmacological literature, not findings of this study. Reporting the twofold prescribing difference as evidence of danger conflates utilization with outcomes, a distinction the study’s descriptive design makes impossible to bridge.

Bottom Line

This large population study establishes that older adults with COPD in Ontario received off-label synthetic oral cannabinoids at roughly twice the rate of those without COPD, at higher doses and for longer durations. These are utilization findings, not safety findings. Whether this prescribing pattern produces respiratory harm remains entirely unknown. The study’s primary value is in identifying a prescribing signal that justifies, but does not substitute for, prospective outcomes research in this vulnerable population.

References

1. Vozoris NT, et al. Incident synthetic oral cannabinoid use among older adults with and without COPD: a population-based cohort study. Retrospective analysis using linked Ontario health administrative databases, study period April 1, 2005 to March 31, 2015.